Manages active classical or definite rheumatoid arthritis (ARA criteria). Sold as Ridaura. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Auranofin (sold as Ridaura), first approved May 24, 1985, with 0 new uses approved and 0 published complete response letters.
| Ridaura | Part D | $835K | -9% | 82 |
| Auranofin | Part D | $33K | New | 15 |
| Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 TherapyAdvanced Melanoma · West China Hospital | Phase 1 | Recruiting | May 1, 2026 |
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsHiv, HIV I Infection · Federal University of São Paulo | Phase 2 | Recruiting | Feb 3, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
